Evaluation of Bioactivity and Pharmacokinetic Characteristics of PEGylated P.pastoris-Expressed Erythropoietin

References

• Agoram B, Aoki K, Doshi S, Gegg C, Jang G, Molineux G, Narhi L, Elliott S. (2008). Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci, 98, 2198–2211.
   Web of Science ®Google Scholar
• Bailon P, Berthold W. (1998). Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today, 1, 352–356.
   Google Scholar
• Boissel JP, Lee WR, Presnell SR, Cohen FE, Bunn HF. (1993). Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure. J Biol Chem, 268, 15983–93.
   PubMed Web of Science ®Google Scholar
• Bradford MM. (1976). A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem, 72, 248–254.
   PubMed Web of Science ®Google Scholar
• Burg J, Engel A, Franze R, et al. (2006). Erythropoietin Conjugates. US Patent, No, 7128913.
   Google Scholar
• Celik E, Calik P, Halloran SM, Oliver SG. (2007). Production of recombinant human erythropoietin from Pichia pastoris; and its structural analysis. J Appl Microbiol, 103, 2084–2094.
   PubMed Web of Science ®Google Scholar
• Celik E, Calik P, Oliver SG (2009). Fed-batch methanol feeding strategy for recombinant protein production by Pichia pastoris in the presence of co-substrate sorbitol. Yeast, 26, 473–484.
   PubMed Web of Science ®Google Scholar
• Daly R, Hearn MTW. (2005). Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. J Mol Recognit, 18, 119–138.
   PubMed Web of Science ®Google Scholar
• Dinkelaar RB, Engels EY, Hart AA, Schoemaker LP, Bosch E, Chamuleau RA. (1981). Metabolic studies on erythropoietin (EP): II. The role of liver and kidney in the metabolism of Ep. Exp Hematol, 9, 796–803.
   PubMed Web of Science ®Google Scholar
• Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. (2003). Darbepoetin alpha has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol, 31, 290–299.
   PubMed Web of Science ®Google Scholar
• Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E. (1997). Mapping of the active site of recombinant human erythropoietin. Blood, 8(9), 493–502.
   Google Scholar
• Elliott S, Pham E, Macdougall IC. (2008). Erythropoietins: a common mechanism of action. Exp Hematol, 36, 1573–1584.
   PubMed Web of Science ®Google Scholar
• Gross AW, Lodish HF. (2006). Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem, 281, 2024–2032.
   PubMed Web of Science ®Google Scholar
• Hamidi M, Azadi A, Rafiei P. (2006). Pharmacokinetic consequences of pegylation. Drug Deliv, 13(6), 399–409.
   PubMed Web of Science ®Google Scholar
• Harris JM, Martin NE, Modi M. (2001). Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet, 40, 539–551.
   PubMed Web of Science ®Google Scholar
• Horton RM (1993). In Vitro Recombination and mutagnesis of DNA: SOIng together tailor-made genes. In: White, BA. (Eds.), Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications. 251–266.Totawa: Humana Press.
   Google Scholar
• Jevsevar S, Kunstelj M, Porekar VG. (2010). PEGylation of therapeutic proteins. Biotechnol J, 5, 113–128.
   PubMed Web of Science ®Google Scholar
• Kapre V, Shaligram S, Nho K, Bae G. (2007). N-Terminal PEG-Conjugate of Erythropoietin. IPP WO/2007/010552.
   Google Scholar
• Kinstler OB, Brems DN, Lauren SL, Paige AG, Hamburger JB, Treuheit MJ. (1996). Characterization and stability of N-terminally PEGylated rhG-CSF. Pharmaceut Res, 13, 996–1002.
   PubMed Web of Science ®Google Scholar
• Kinstler OB, Gabriel NE, Farrar CE, DePrince RB. (1999). N-terminally chemically modified protein compositions and method. US Patent, No, 5985265.
   Google Scholar
• Komatsu N, Nakauchi H, Miwa A, Ishihara T, et al. (1991). Establishment and Characterization of a Human Leukemic Cell Line with Megakaryocytic Features: Dependency on Granulocyte-Macrophage Colony-stimulating Factor, Interleukin 3, or Erythropoietin for Growth and Survival. Cancer Res, 51, 341–348.
   PubMed Web of Science ®Google Scholar
• Kurfurst MM. (1992). Detection and molecular-weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl-sulfate polyacrylamide-gel electrophoresis. Anal Biochem, 200, 244–248.
   PubMed Web of Science ®Google Scholar
• Kusterle M, Jevsevar S, Porekar VG. (2008). Size of Pegylated Protein Conjugates Studied by Various Methods. Acta Chim Slov, 55, 594–601.
   Web of Science ®Google Scholar
• Laemmli UK (1970). Cleavage of structural proteins during assembly of head of bacteriophage-T4. Nature, 227, 680–685.
   PubMed Web of Science ®Google Scholar
• Leist M, Ghezzi P, Grasso G, et al. (2004). Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science, 305, 239–242.
   PubMed Web of Science ®Google Scholar
• Li P, Anumanthan A, Gao XG, Ilangovan K, Suzara VV, et al. (2007). Expression of recombinant proteins in Pichia pastoris. Appl Biochem Biotechnol, 142(2), 105–24.
   PubMed Web of Science ®Google Scholar
• Long DL, Doherty DH, Eisenberg SP, et al. (2006). Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity. Exp Hematol, 34, 697–704.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Roberts DE, Coles GA, Williams JD. (1991). Clinical pharmacokinetics of Epoetin (recombinant human erythropoietin). Clin Pharmacokinet, 20, 99–113.
   PubMed Web of Science ®Google Scholar
• Markham A, Bryson HM. (1995). Epoetin alpha. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs, 49, 232–254.
   PubMed Web of Science ®Google Scholar
• McGoff P, Baziotis AC, Maskiewicz R. (1988). Analysis of polyethylene glycol modified superoxide dismutase by chromatographic, electrophoretic, light scattering, chemical and enzymatic methods. Chem Pharm Bull, 36(8), 3079–3091.
   PubMed Web of Science ®Google Scholar
• Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J mmunol Methods, 65, 55–63.
   PubMed Web of Science ®Google Scholar
• Narhi LO, Arakawa T, Aoki KH, Elmore R, Rohde MF, Boone T, Strickland TW. (1991). The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem, 266, 23022–6.
   PubMed Web of Science ®Google Scholar
• Spivak JL, Hogans BB (1989). The in vivo metabolism of recombinant human erythropoietin in the rat. Blood, 73, 90–99.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Takasaki S, Shimada M, Robata A. (1990). Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese Hamster Ovary Cells. J Biol Chem, 265, 12127–30.
   PubMed Web of Science ®Google Scholar
• Wang Y-J, Hao S-J, Liu Y-D, Hu T, et al. (2010). PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: A comparison with glycosylated erythropoietin. J Control Release, 145, 306–313.
   PubMed Web of Science ®Google Scholar
• Wasley LC, Timoney G, Murtha P, et al. (1991).The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin.Blood, 77, 2624–2632.
   PubMed Web of Science ®Google Scholar
• Wei Z, Menon-Rudolph S, Ghosh-Dastidar P. (2000). Methods and kits for making polypeptides having a single covalently bound N-terminal water soluble polymer. US Patent, No, 6077939.
   Google Scholar
• Wojchowski DM, Caslake L. (1989). Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligand. Blood, 74, 952–958.
   PubMed Web of Science ®Google Scholar
• Yesland KD. (2008). Pharmacodynamically enhanced therapeutics proteins. US Patent, gt;No, 2008/0171696.
   Google Scholar